Biologics Safety Testing Market Overview
The Biologics Safety Testing Market is expanding as pharmaceutical and biotechnology companies increase the development and manufacturing of vaccines, therapeutic proteins, cell and gene therapies, and other complex biological products. The growing complexity of biologics pipelines is increasing the need for comprehensive safety testing throughout development and manufacturing. Regulatory requirements, contamination control, and the need to ensure product quality are also encouraging manufacturers to adopt advanced testing technologies and specialized services.
According to the Market Research Future report updated August 24, 2026, the Biologics Safety Testing Market was valued at USD 3,998.79 Million in 2024 and is projected to grow from USD 4,542.71 Million in 2025 to USD 16,262.06 Million by 2035, registering a CAGR of 13.6% during 2025–2035. North America led the market with more than 49.97% share in 2024, while Europe accounted for approximately 30%. Sterility Testing represented the largest application segment with 32% share, Biological Assays held the largest test-type share at 70%, and Pharmaceutical Companies accounted for approximately 65% of the end-user market. Molecular Assays and Biotechnology Companies are among the fastest-growing segments.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/biologics-safety-testing-market-6800
Key players driving innovation and competitiveness in the Biologics Safety Testing Market include:
Charles River Laboratories
Eurofins Scientific
Sartorius AG
Merck KGaA
Thermo Fisher Scientific
Lonza Group
WuXi AppTec
SGS SA
Boehringer Ingelheim
The market is being shaped by the rapid expansion of biologics manufacturing and increasingly stringent regulatory requirements for safety, quality, and contamination control. Pharmaceutical manufacturers need comprehensive testing programs to identify potential microbial contamination, adventitious agents, endotoxins, and other safety risks throughout the product lifecycle.
Technological advancement is also changing the testing landscape. Molecular techniques, automation, high-throughput screening, advanced analytical methods, and next-generation sequencing are improving testing speed and sensitivity. Automated systems can provide faster contamination monitoring, which is particularly relevant for cell and gene therapies where reducing testing turnaround times can support more efficient product release.
The Biologics Safety Testing Market can be segmented by application, test type, end user, and region. Application categories include Cell Line Development, Bioburden Testing, Sterility Testing, Endotoxin Testing, and Virus Safety Testing. Sterility Testing currently represents the largest application segment because of its critical role in confirming that biologic products are free from viable microorganisms, while Endotoxin Testing is gaining momentum because of increasing regulatory emphasis on product safety.
By test type, Biological Assays represent the largest category, accounting for approximately 70% of the market. Molecular Assays are experiencing faster growth because technologies such as PCR and next-generation sequencing can provide rapid and highly sensitive detection. These methods are increasingly relevant as manufacturers seek to improve testing efficiency while maintaining stringent quality standards.
Pharmaceutical Companies represent the largest end-user segment because of their extensive biologics development and manufacturing activities. Biotechnology Companies are growing rapidly as innovative therapies and smaller specialized pipelines expand. Contract Research Organizations are also becoming increasingly important as pharmaceutical and biotechnology companies outsource specialized testing to access advanced laboratories, expertise, and validated technologies without making equivalent investments in internal infrastructure.
Outsourcing is therefore creating significant opportunities across the market. Biopharmaceutical companies can use specialized testing providers for sterility, endotoxin, viral safety, microbial testing, and analytical characterization while focusing internal resources on drug development and manufacturing. Emerging markets also present opportunities as local biologics production expands and manufacturers seek to meet international safety and quality standards.
Recent Developments and Market Trends:
Automation is increasingly being adopted to improve testing speed, reproducibility, and contamination monitoring in biologics manufacturing.
Molecular assays are gaining importance as pharmaceutical companies seek faster and more sensitive approaches to biologics safety evaluation.
The outsourcing of specialized testing services is expanding as biotechnology companies seek access to advanced laboratories and technical expertise.
Cell and gene therapy development is creating demand for rapid sterility and contamination-testing technologies capable of supporting time-sensitive manufacturing workflows.
Regulatory scrutiny and evolving safety standards are encouraging manufacturers to invest in validated testing technologies and stronger quality-control systems.
Reasons to Buy the Report:
Understand the current size and projected growth trajectory of the Biologics Safety Testing Market.
Analyze application, test-type, end-user, and regional market segments.
Review major companies and their competitive positions in biologics safety testing.
Identify opportunities associated with molecular assays, automation, outsourcing, and advanced therapies.
Assess regulatory, technological, and manufacturing trends influencing the market through 2035.
Future Outlook:
The Biologics Safety Testing Market is expected to maintain strong growth as biologics, vaccines, cell therapies, and gene therapies become increasingly important within pharmaceutical pipelines. Sterility Testing is expected to remain the largest application category, while Endotoxin Testing and advanced molecular approaches should continue gaining importance.
North America is expected to maintain its leading regional position because of its established pharmaceutical infrastructure, strong regulatory environment, and significant biologics R&D activity. Asia-Pacific is expected to offer substantial growth opportunities as local biologics manufacturing, healthcare investment, and regulatory capabilities continue to develop.
Through 2035, automation, molecular testing, rapid microbial methods, outsourcing, and advanced analytical technologies are expected to reshape biologics safety testing workflows. The market is projected to reach USD 16,262.06 Million, or approximately USD 16.26 Billion, by 2035 at a 13.6% CAGR.
➤➤Explore Our Latest Related Reports:
